LYCOS RETRIEVER 
Rheumatoid Arthritis
built 640 days ago
The second technology focuses on new immune response modifiers -- PXS25 and PXS2000 -- for the treatment of multiple sclerosis and rheumatoid arthritis. The company has a pipeline of products in different stages of development, including four projects at clinical study stage (in patients), two projects in pre-clinical evaluation, and one research project to identify a compound for development.
Source:
MORE ABOUT
Studies